Healthcare Industry News: personalized oncology
News Release - September 16, 2010
Metamark Genetics, Inc. Announces New Chief Scientific OfficerExperienced oncology leader to rapidly expand R&D efforts to pinpoint the mechanisms governing tumor aggression and response to therapy
CAMBRIDGE, Mass., Sept. 16 -- (Healthcare Sales & Marketing Network) -- Metamark Genetics, Inc., a privately held molecular diagnostics company developing innovative personalized medicine approaches to optimize cancer care, announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. as Chief Scientific Officer.
Dr. Blume-Jensen joins Metamark with over 20 years of experience in cancer research and oncology drug discovery. From 2001 to 2008 Dr. Blume-Jensen was department head at EMD Serono, Inc. and later at Merck Research Laboratories, Merck & Co, Inc. where he established integrated oncology R&D programs linking therapeutics to patient responder populations. During his tenure he advanced a number of pre-clinical drug programs into the clinic, and provided translational support for clinical programs. Since 2008 he served as Exec. Dir., External Scientific Affairs and Vice President of Daiichi Sankyo Research Institute, Daiichi Sankyo Inc., was 'Therapeutic Area Advisor' for Oncology, and helped formulate a global oncology R&D strategy. Dr. Blume-Jensen's pioneering work on oncogenic signaling, disease mouse models, and more recently efficacy-predictive biomarkers for oncology therapeutics is highly cited. Dr. Blume-Jensen obtained his M.D. from Copenhagen, Denmark, his Ph.D. from Dr. Carl-Henrik Heldin's laboratory at the Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral studies in Dr. Tony Hunter's laboratory at the Salk Institute, La Jolla, CA.
Kenneth E. Weg, Metamark's Chairman and CEO stated, "Metamark is very fortunate to have attracted a true leader in the personalized oncology movement to shepherd Metamark's ambitious Research and Development efforts. We welcome Dr. Blume-Jensen to the expanding Metamark team."
Dr. Blume-Jensen stated, "I am very excited about the innovative, function-driven Metamark platform and the opportunity to join the Metamark team to help catapult the launch of the first MetamarkDx™ Prognostic Assays. I am looking forward to applying my expertise in personalized oncology medicine and predictive biomarkers to help transform Metamark into the leading next generation molecular diagnostics company."
Cautionary Note Regarding Forward-Looking Statements
This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results, are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.
Source: Metamark Genetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.